OncoMatch/Clinical Trials/NCT06963216
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Is NCT06963216 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Coagadex(R) for acquired factor x deficiency.
Treatment: Coagadex(R) — The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: factor X containing product
Any factor X containing product taken within 2 weeks of first Coagadex® administration
Cannot have received: anticoagulant therapy
Exception: antiplatelets permitted
On anticoagulant therapy (not antiplatelets)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Mayo Clinic Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify